MCID: MLT019
MIFTS: 77

Multiple Myeloma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Blood diseases, Immune diseases

Aliases & Classifications for Multiple Myeloma

About this section
Sources:
49OMIM, 32LifeMap Discovery®, 10Disease Ontology, 11diseasecard, 45NIH Rare Diseases, 22GeneTests, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 36MeSH, 35MedlinePlus, 65UMLS, 47Novoseek, 24GTR, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Multiple Myeloma:

Name: Multiple Myeloma 49 32 10 11 45 22 12 51 67 36 35 65
Plasma Cell Myeloma 10 45 47 51
Medullary Plasmacytoma 51 65
Plasma Cell Dyscrasia 45 65
Myeloma - Multiple 45 24
 
Myelomatosis 45 51
Plasma Cell Neoplasm 65
Kahler's Disease 51
Kahler Disease 45
Mm 67

Characteristics:

Orphanet epidemiological data:

51
multiple myeloma:
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult

HPO:

61
multiple myeloma:
Inheritance: somatic mutation, autosomal recessive inheritance


Classifications:



External Ids:

OMIM49 254500
Disease Ontology10 DOID:9538
ICD1027 C90.0, C90.00
ICD9CM29 203.0
MeSH36 D009101
NCIt42 C3242
Orphanet51 29073
ICD10 via Orphanet28 C90.0
MESH via Orphanet37 D009101
UMLS via Orphanet66 C0026764
UMLS65 C0026764, C1959632, C2854075

Summaries for Multiple Myeloma

About this section
NIH Rare Diseases:45 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. when present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. the exact underlying cause of multiple myeloma is currently unknown. factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, african american race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (mgus). treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting. last updated: 3/12/2016

MalaCards based summary: Multiple Myeloma, also known as plasma cell myeloma, is related to plasmacytoma and human herpesvirus 8, and has symptoms including multiple myelomaand abnormality of metabolism/homeostasis. An important gene associated with Multiple Myeloma is LIG4 (DNA Ligase 4), and among its related pathways are Cytokine production by Th17 cells in CF and Hematopoietic cell lineage. The drugs cyclophosphamide and thalidomide have been mentioned in the context of this disorder. Affiliated tissues include the plasma cells in bone marrow, bone and bone marrow, and related mouse phenotypes are tumorigenesis and nervous system.

Disease Ontology:10 A myeloma that is located in the plasma cells in bone marrow.

UniProtKB/Swiss-Prot:67 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

MedlinePlus:35 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bones. no one knows the exact causes of multiple myeloma, but it is more common in older people and african americans. it can run in families. common symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss frequent infections and fevers feeling very thirsty frequent urination doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. your treatment depends on how advanced the disease is and whether you have symptoms. if you have no symptoms, you may not need treatment right away. if you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

Genetics Home Reference:23 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.

OMIM:49 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells... (254500) more...

Wikipedia:68 Multiple myeloma is a cancer of plasma cells, a type of white blood cell normally responsible for... more...

Related Diseases for Multiple Myeloma

About this section

Diseases in the Myeloma family:

multiple myeloma Igh-Related Multiple Myeloma

Diseases related to Multiple Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 412)
idRelated DiseaseScoreTop Affiliating Genes
1plasmacytoma33.3CCND1, IL6
2human herpesvirus 830.3IL6, IL6R
3igh-related multiple myeloma12.0
4myeloma11.8
5plasma cell neoplasm11.3
6plasma cell leukemia11.1
7indolent myeloma11.0
8miyoshi muscular dystrophy 110.9
9medial medullary syndrome10.9
10catamenial pneumothorax10.9IL6, IL6R
11solitary osseous plasmacytoma10.9CCND1, IL6, IL6R
12multicentric osteolysis nephropathy10.8IL6, IL6R
13extramedullary plasmacytoma10.8
14plasmablastic lymphoma10.8CCND1, FGFR3, IRF4, MAF, NCAM1
15hematopoietic stem cell transplantation10.8
16primary gastrointestinal melanoma10.7IL6, IRF4
17osteogenesis imperfecta, type x10.7IL6, IL6R
18megakaryocytic leukemia10.7CCND1, CD19, IRF4
19lymphoma, malt, somatic10.7CCND1, CD19, IRF4
20monoclonal gammopathy of uncertain significance10.7
21light chain deposition disease10.7
22aortitis10.7MAF, NCAM1
23cryoglobulinemia10.6
24solitary plasmacytoma of chest wall10.6CD19, MCL1, NCAM1
25leukemia10.5
26diffuse intraductal papillomatosis10.5CD19, IL6, MAF, NCAM1, WHSC1
27cell type benign neoplasm10.5CCND1, CD19, IL6, MCL1, NCAM1
28cell type cancer10.5CCND1, CD19, IL6, MCL1, NCAM1
29overnutrition10.5CD19, FGFR3, IL6, MAF, NCAM1, WHSC1
30lymphoma10.5
31epidermolysis bullosa acquisita10.5
32smoldering myeloma10.4
33hypoaldosteronism10.4
34leukemia, acute myeloid10.4CD19, IL6, MCL1, NCAM1
35amyloidosis10.4
36bone diseases10.4
37endotheliitis10.4
38marginal zone b-cell lymphoma10.3CCND1, CCND3, CD19, MCL1
39smoking as a quantitative trait locus 110.3CCND1, CCND3, CD19, IRF4, MCL1
40macroglobulinemia10.2
41al amyloidosis10.2
42neuropathy10.2
43chronic lymphocytic leukemia10.1
44glomerulonephritis10.1
45peripheral neuropathy10.1
46cutis laxa10.1
47purpura10.1
48hodgkin lymphoma10.1
49acquired cutis laxa10.1
50behcet's disease10.1CCND1, CCND3, IRF4

Graphical network of the top 20 diseases related to Multiple Myeloma:



Diseases related to multiple myeloma

Symptoms for Multiple Myeloma

About this section

Symptoms by clinical synopsis from OMIM:

254500

Clinical features from OMIM:

254500

HPO human phenotypes related to Multiple Myeloma:

id Description Frequency HPO Source Accession
1 multiple myeloma HP:0006775
2 abnormality of metabolism/homeostasis HP:0001939

Drugs & Therapeutics for Multiple Myeloma

About this section

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s)15 Company Approval Date
1
Aredia15 41 PAMIDRONATE DISODIUM Chiron August 1996
FDA Label: Aredia
Disease/s that Drug Treats:osteolytic bone metastases of breast cancer
Indications and Usage:15 Hypercalcemia of MalignancyAredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severehypercalcemia associated with malignancy, with or without bone metastases. Patients who have eitherepidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, anintegral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made torestore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia maybe treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patientsshould be hydrated adequately throughout the treatment, but overhydration, especially in those patientswho have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction ofhypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated withhyperparathyroidism or with other non-tumor-related conditions has not been established.Paget’s DiseaseAredia is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Theeffectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase ≥3 timesthe upper limit of normal. Aredia therapy in patients with Paget’s disease has been effective in reducingserum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by≥30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemicalmarkers in patients with Paget’s disease who failed to respond, or no longer responded to othertreatments.Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of MultipleMyelomaAredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolyticbone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effectappeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the studyof those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated(see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and OsteolyticLesions of Multiple Myeloma, Clinical Trials section).
DrugBank Targets:13 1. Farnesyl pyrophosphate synthase;2. Hydroxylapatite
Mechanism of Action:15 
Target: bone resorption; FPP synthase
Action: inhibitor
FDA: The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism ofantiresorptive action is not completely understood, several factors are thought to contribute to this action.Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolutionof this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activitycontributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment ofhypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation andmineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Arediainhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by varioustumors in animal studies.
2
Busulfex15 41 BUSULFAN Orphan Medical February 1999
FDA Label: Busulfex
Disease/s that Drug Treats:leukemia
Indications and Usage:15 BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
DrugBank Targets:13 DNA
Mechanism of Action:15 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
3
Doxil15 41 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:15 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:13 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:15 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
4
Evista15 41 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
FDA Label: Evista
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:15 EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:13 1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:15 
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
5
Farydak15 41 PANOBINOSTAT LACTATE Novartis February 2015
FDA Label: Farydak
Disease/s that Drug Treats:Multiple myeloma
Indications and Usage:15 FARYDAK, a histone deacetylase inhibitor, in combination with bortezomiband dexamethasone, is indicated for the treatment of patients with multiplemyeloma who have received at least 2 prior regimens, including bortezomiband an immunomodulatory agent. This indication is approved underaccelerated approval based on progression free survival. Continued approvalfor this indication may be contingent upon verification and description ofclinical benefit in confirmatory trials. (1)
DrugBank Targets: -
Mechanism of Action:15 
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: FARYDAK is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs atnanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histonesand some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins,an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation. In vitro,Reference ID: 3699607 panobinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/orapoptosis of some transformed cells. Increased levels of acetylated histones were observed in xenografts frommice that were treated with panobinostat. Panobinostat shows more cytotoxicity towards tumor cells comparedto normal cells.
6
Kyprolis15 41 CARFILZOMIB Onyx Pharmaceuticals July 2012
FDA Label: Kyprolis
Disease/s that Drug Treats:multiple myeloma
Indications and Usage:15 Kyprolis is a proteasome inhibitor that is indicated in combination with lenalidomide and dexamethasone for the treatment ofpatients with relapsed multiple myeloma who have received one to threeprior lines of therapy . (1, 14) as a single agent for the treatment of patients with multiple myeloma whohave received at least two prior therapies including bortezomib and animmunomodulatory agent and have demonstrated disease progression on orwithin 60 days of completion of the last therapy. Approval is based onresponse rate. Clinical benefit, such as improvement in survival orsymptoms, has not been verified. (1, 14)
DrugBank Targets:13 1. Proteasome subunit beta type-5;2. Proteasome subunit beta type-8;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-9;5. Proteasome subunit beta type-2;6. Proteasome subunit beta type-10
Mechanism of Action:15 
Target: tetrapeptide epoxyketone proteasome
Action: inhibitor
FDA: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to theN-terminal threonine-containing active sites of the 20S proteasome, the proteolytic coreparticle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptoticactivities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibitedproteasome activity in blood and tissue and delayed tumor growth in models of multiplemyeloma, hematologic, and solid tumors.
7
Mozobil15 41 PLERIXAFOR Genzyme December 2008
FDA Label: Mozobil
Disease/s that Drug Treats:non-Hodgkin’s lymphoma and multiple myeloma
Indications and Usage:15 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combinationwith granulocyte-colony stimulating factor (G-CSF) to mobilizehematopoietic stem cells (HSCs) to the peripheral blood for collection andsubsequent autologous transplantation in patients with non-Hodgkin’slymphoma and multiple myeloma. (1)
DrugBank Targets:13 1. C-X-C chemokine receptor type 4
Mechanism of Action:15 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognateligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play arole in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrowcompartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to themarrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules.Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoieticprogenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable ofengraftment with long-term repopulating capacity up to one year in canine transplantationmodels.
8
Pomalyst15 41 POMALIDOMIDE Celgene February 2013
FDA Label: Pomalyst
Disease/s that Drug Treats:relapsed and refractory multiple myeloma
Indications and Usage:15 POMALYST is a thalidomide analogue indicated, in combination withdexamethasone, for patients with multiple myeloma who have received atleast two prior therapies including lenalidomide and a proteasome inhibitorand have demonstrated disease progression on or within 60 days ofcompletion of the last therapy (1.1).
DrugBank Targets:13 1. Protein cereblon;2. Tumor necrosis factor;3. Prostaglandin G/H synthase 2
Mechanism of Action:15 
Target: hematopoietic tumor cells, lenalidomide-resistant multiple myeloma cell lines/ T-cells
Action: inhibitor of proliferation/ inducer of apoptosis/ enhancer of natural killer cell-mediated immunity
FDA: Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplasticactivity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation oflenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in bothlenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis.Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibitedproduction of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomidedemonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cordmodel.
9
Revlimid15 41 LENALIDOMIDE Celgene June 2013
FDA Label: Revlimid
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:15 REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:13 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:15 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
10
Sprycel15 41 DASATINIB Bristol-Myers Squibb June 2006
FDA Label: Sprycel
Disease/s that Drug Treats:Chronic Myeloid Leukemia
Indications and Usage:15 SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:13 1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn
Mechanism of Action:15 
Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.
11
Subsys15 FENTANYL Insys Therapeutics January of 2012
FDA Label: Subsys
Disease/s that Drug Treats:breakthrough cancer pain
Indications and Usage:15 SUBSYS is an opioid agonist indicated for the management of breakthroughpain in cancer patients 18 years of age and older who are already receivingand who are tolerant to opioid therapy for their underlying persistent cancerpain. Patients must remain on around-the-clock opioids when takingSUBSYS. (1)Limitations of Use:SUBSYS may be dispensed only to patients enrolled in the TIRF REMSACCESS program.
DrugBank Targets:13 1. Mu-type opioid receptor;2. Delta-type opioid receptor;3. Kappa-type opioid receptor
Mechanism of Action:15 
Target: opiod receptors?
Action: agonist
FDA: Fentanyl is an opioid agonist whose principal therapeutic action is analgesia.Other members of the class known as opioid agonists include substances such asmorphine, oxycodone, hydromorphone, codeine, and hydrocodone.
12
Velcade15 41 BORTEZOMIB Millennium Pharmaceuticals May 2003
FDA Label: Velcade
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:15 VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:13 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:15 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.
13
Xgeva15 41 DENOSUMAB Amgen June 2013/ November 2010
FDA Label: Xgeva
Disease/s that Drug Treats:giant cell tumor of bone/ prevention of skeletal-related events in patients with bone metastases from solid tumors
Indications and Usage:15 Xgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with bone metastasesfrom solid tumors (1.1) Treatment of adults and skeletally mature adolescents with giant celltumor of bone that is unresectable or where surgical resection is likely toresult in severe morbidity (1.2, 14.2) Treatment of hypercalcemia of malignancy refractory to bisphosphonatetherapy (1.3)Limitation of use: Xgeva is not indicated for the prevention of skeletal-relatedevents in patients with multiple myeloma
DrugBank Targets:13 1. Tumor necrosis factor ligand superfamily member 11
Mechanism of Action:15 
Target: RANKL
Action: modulator of calcium release
FDA: Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, andsurvival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release frombone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solidtumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressingRANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANKreceptor contributes to osteolysis and tumor growth. Xgeva prevents RANKL from activating itsreceptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
14
Zoladex15 41 GOSERELIN ACETATE AstraZeneca January 1996
FDA Label: Zoladex
Disease/s that Drug Treats:prostate cancer
Indications and Usage:15 ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicatedfor: Use in combination with flutamide for the management of locally confinedcarcinoma of the prostate (1.1) Palliative treatment of advanced carcinoma of the prostate (1.2) The management of endometriosis (1.3) Use as an endometrial-thinning agent prior to endometrial ablation fordysfunctional uterine bleeding (1.4) Use in the palliative treatment of advanced breast cancer in pre- andperimenopausal women (1.5)
DrugBank Targets:13 1. Lutropin-choriogonadotropic hormone receptor;2. Gonadotropin-releasing hormone receptor
Mechanism of Action:15 
Target: pituitary gonadotropinsecretion
Action: inhibitor
FDA: ZOLADEX is a synthetic decapeptide analogue of GnRH. ZOLADEX acts as an inhibitor of pituitary gonadotropinsecretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelinresulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-inducedrat mammary tumor and Dunning R3327 prostate tumor.
15
Zometa15 41 ZOLEDRONIC ACID Novartis August 2001/ February 2002
FDA Label: Zometa
Disease/s that Drug Treats:Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:15 Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bonemetastases from solid tumors, in conjunction with standard antineoplastictherapy. Prostate cancer should have progressed after treatment with atleast one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not beenestablished for use in hyperparathyroidism or nontumor-relatedhypercalcemia. (1.3)
DrugBank Targets:13 1. Farnesyl pyrophosphate synthase;2. Geranylgeranyl pyrophosphate synthase;3. Hydroxylapatite
Mechanism of Action:15 
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although theantiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid alsoblocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acidinhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factorsreleased by tumors.
16
Adempas15 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
FDA Label: Adempas
Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Indications and Usage:15 Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)
DrugBank Targets: -
Mechanism of Action:15 
Target: soluble guanylate cyclase (sGC)
Action: stimulator
FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.
17
Vibativ15 * TELAVANCIN * TELAVANCIN HYDROCHLORIDE Theravance June 2013
FDA Label: Vibativ
Disease/s that Drug Treats:hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus
Indications and Usage:15 VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: * Complicated skin and skin structure infections (cSSSI) (1.1) * Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus. VIBATIV should be reserved for use when alternative treatments are not suitable. (1.2)
DrugBank Targets: -
Mechanism of Action:15 
Target: late-stage peptidoglycan precursors
Action: inhibits cell wall biosynthesis
FDA: Telavancin is an antibacterial drug [see Clinical Pharmacology (12.4)]. Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telavancin also binds to the bacterial membrane and disrupts membrane barrier function.

Drugs for Multiple Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 615)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Dexamethasoneapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
2
FludarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
3
VidarabineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 023824356-66-932326, 21704
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
ADENOSINE, U.S.P.
ADN
AI3-52413
AI3-52821
AR-1H6029
ARA-A NSC 247519
Ade-Rib
Adenine Arabinoside
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
Adenosine-8-14C
Adensoine
Ambap5536-17-4
Ara A
Ara-A
Ara-ATP
Araadenosine
Arabinoside Adenine
Arabinoside adenine
Arabinosyl Adenine
Arabinosyl adenine
Arabinosyl-adenine
Arabinosyladenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
Bio1_000437
Bio1_000926
Bio1_001415
Boniton
C00212
CAS-5536-17-4
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
Caswell No. 010B
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
 
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
LS-15059
LS-15085
Lopac0_000123
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC-404241
NSC247519
NSC404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
PDSP1_001036
PDSP2_001020
Pallacor
Polyadenosine
Polyriboadenosine
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
Prestwick_983
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
SPECTRUM1500107
SPECTRUM1500609
SR 96225
SR-96225
STK361815
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spectrum_001894
Spongoadenosine
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
VIRDARABINE
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
adenine-D-ribose
adenosine
alpha-Ara A
beta-Adenosine
beta-Ara A
beta-D-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
4
PiperacillinapprovedPhase 4, Phase 38666258-76-243672
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AC1L2ACR
AC1Q5QXJ
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
D08380
EINECS 262-811-8
HMS2090H19
LS-149794
 
PIPC
PIPERACILLIN SODIUM
Peperacillin
Peracin
Peracin (TN)
Piperacilina
Piperacillin
Piperacillin (INN)
Piperacillin (anhydrous)
Piperacillin Anhydrous
Piperacillin Monosodium Salt
Piperacillin Sodium
Piperacillin anhydrous
Piperacillina
Piperacillinum
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Pipéracilline
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
SPBio_002709
T-1220
UNII-9I628532GX
piperacillin
5
EpirubicinapprovedPhase 4, Phase 3, Phase 236156420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
6
TazobactamapprovedPhase 4, Phase 38789786-04-9123630
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC-7620
AC1L3X07
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
 
CID123630
CL-298741
CL298741
D00660
DB01606
MolPort-002-500-123
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
YTR-830H
YTR830H
7
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
8
MelphalanapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
9
ThiotepaapprovedPhase 4, Phase 2, Phase 120552-24-45453
Synonyms:
 
Thioplex
10
Epoetin alfaapprovedPhase 4, Phase 3, Phase 2626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
11
Busulfanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 150655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
12
PrednisoneapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0126753-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
Juvason
 
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Perrigo Prednisone
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rayos
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
13
LenalidomideapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0674191732-72-6216326
Synonyms:
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
191732-72-6
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
346670-73-3
443912-14-9
AC-914
AC1L50II
AKOS005146276
ALBB-015321
Bio-0168
C467567
CC 5013
CC-5013
CC-5013, Revlimid, Lenalidomide
CC5013
CDC 501
CDC-501
CDC-5013
CHEMBL848
CID216326
Celgene brand of lenalidomide
D04687
 
DB00480
EC-000.2340
ENMD-0997
I06-0831
IMID-1
IMID-5013
IMiD3
IMiD3 cpd
IMid-1
LS-184040
Lenalidomide
Lenalidomide (USAN/INN)
Lenalidomide [USAN]
MolPort-003-848-370
NCGC00167491-01
NSC747972
Revamid
Revimid
Revlimid
Revlimid (Celgene)
Revlimid (TN)
S1029_Selleck
STK639603
Thalidomide analog CC-5013
UNII-F0P408N6V4
lenalidomide
14
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
15
PhentolamineapprovedPhase 41550-60-25775
Synonyms:
2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline
2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline
2-(N-(m-Hydroxyphenyl)-P-toluidinomethyl)imidazoline
2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline
2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline
3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
5-25-09-00365 (Beilstein Handbook Reference)
50-60-2
65-28-1 (mesylate (salt))
73-05-2 (mono-hydrochloride)
AC1L1L3Z
AC1Q2KIW
AKOS004119917
BCBcMAP01_000014
BPBio1_000307
BRD-K90333595-001-02-8
BRD-K90333595-003-04-0
BRN 0272944
BSPBio_000279
BSPBio_001435
BSPBio_002496
C 7337
C 7337 Ciba
C17H19N3O
CAS-73-05-2
CHEBI:120131
CHEMBL597
CID5775
D08362
DB00692
Dibasin
DivK1c_000807
EINECS 200-053-1
Fentolamin
Fentolamina
Fentolamina [INN-Spanish]
HMS1791H17
HMS1989H17
HMS2089E03
HSDB 3382
IDI1_000807
KBio1_000807
KBio2_000477
KBio2_003045
KBio2_005613
KBio3_001716
KBioGR_001338
KBioSS_000477
L001116
 
LS-104396
Lopac0_000982
MLS000040874
MLS001201741
MolPort-001-783-569
NCGC00016311-01
NCGC00016311-02
NCGC00016311-03
NCGC00016311-15
NCGC00021804-06
NCGC00021804-07
NCGC00021804-08
NCGC00021804-09
NCGC00021804-10
NINDS_000807
Oraverse
Phenotolamine
Phentalamine
Phentolamin
Phentolamine
Phentolamine (INN)
Phentolamine Mesylate
Phentolamine [INN:BAN]
Phentolamine mesylate
Phentolamine mesylate [USAN]
Phentolamine methanesulfonate
Phentolamine, methyl sulfonate
Phentolaminum
Phentolaminum [INN-Latin]
Prestwick0_000230
Prestwick1_000230
Prestwick2_000230
Prestwick3_000230
Regitin
Regitina
Regitine
Regitipe
Regityn
Rogitine
SMP1_000236
SMR000058051
SPBio_002200
STK802099
STOCK4S-00358
Spectrum3_000788
Spectrum4_000899
Spectrum5_001704
Spectrum_000077
UNII-Z468598HBV
Vesomax
nchembio705-6
phentolamine
16
Bortezomibapproved, investigational, experimentalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0769179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
17
IronapprovedPhase 4, Phase 3, Phase 2, Phase 110217439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Dexiron
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Ed-In-Sol
 
Eisen
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feraheme
Feronate
Ferretts
Ferrlecit
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Infufer
Iron
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Yieronia
fer
ferrous ascorbate
ferrous fumarate
ferrous gluconate
ferrous glycine sulfate
ferrous iron
ferrous succinate
ferrous sulfate
hierro
18
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
19Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09140
20Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03611
21Dexamethasone acetatePhase 4, Phase 3, Phase 2, Phase 1, Phase 019091177-87-3
22Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
23BB 1101Phase 4, Phase 3, Phase 2, Phase 1, Phase 01909
24Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 2, Phase 1, Phase 01909
25Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03688
26Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
27Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
28Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 14081
29Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 1, Phase 05971
30Antibodies, MonoclonalPhase 4, Phase 3, Phase 2, Phase 12413
31Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 15770
32AntibodiesPhase 4, Phase 3, Phase 2, Phase 14477
33JM 3100Phase 4, Phase 3, Phase 2, Phase 1, Phase 0125
34AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 19454
35AntiemeticsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03213
36DaratumumabPhase 4, Phase 2, Phase 3, Phase 119
37Piperacillin, tazobactam drug combinationPhase 4, Phase 368
38Fludarabine phosphatePhase 4, Phase 3, Phase 2, Phase 1, Phase 0105930751
39
MesnaPhase 4, Phase 3, Phase 2, Phase 12433375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
CoM
Coenzyme M
HS-CoM
40Beta-Lactamase InhibitorsPhase 4, Phase 3245
41ParaproteinsPhase 4, Phase 3, Phase 2, Phase 122
42Ferric CompoundsPhase 4, Phase 3122
43Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08071
44ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 14477
45Myeloma ProteinsPhase 4, Phase 3, Phase 2, Phase 122
46Penicillanic AcidPhase 459
47Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09988
48HormonesPhase 4, Phase 3, Phase 2, Phase 1, Phase 011748
49
PanobinostatPhase 4, Phase 3, Phase 1, Phase 2132404950-80-76918837
Synonyms:
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
FT-0083488
Faridak
 
LBH 589
LBH-589
LBH-589B
LBH589
MolPort-005-933-338
NVP-LBH-589
NVP-LBH589
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
nchembio.313-comp11
50Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510

Interventional clinical trials:

(show top 50)    (show all 2099)
idNameStatusNCT IDPhase
1Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 4
2A Multiple Myeloma Trial in Patients With Bone MetastasesCompletedNCT00104104Phase 4
3A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396Phase 4
4Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early BortezomibCompletedNCT01060202Phase 4
5Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma PatientsCompletedNCT00622505Phase 4
6Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4
7Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
8Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.CompletedNCT01026701Phase 4
9Quality of Life in Multiple Myeloma Patients Treated With BortezomibCompletedNCT01021592Phase 4
10Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaCompletedNCT02474563Phase 4
11A Retreatment Study With Bortezomib for Multiple MyelomaCompletedNCT01030302Phase 4
12Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
13An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245Phase 4
14VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the NetherlandsCompletedNCT00440765Phase 4
15ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.CompletedNCT00440479Phase 4
16PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC TransplantationCompletedNCT00352703Phase 4
17Retrospective Survey of Re-treatment With BortezomibCompletedNCT01524445Phase 4
18Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
19FREE Study - Fracture Reduction EvaluationCompletedNCT00211211Phase 4
20Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)CompletedNCT01005628Phase 4
21Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
22Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving ChemotherapyCompletedNCT00524407Phase 4
23Clinical And Economic Impact Of Upfront Plerixafor In Autologous TransplantationCompletedNCT01339572Phase 4
24Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4
25Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533Phase 4
26Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous TransplantationCompletedNCT01738373Phase 4
27CAFE Study - Cancer Patient Fracture EvaluationCompletedNCT00211237Phase 4
28Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaRecruitingNCT02559583Phase 4
29A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaRecruitingNCT02268890Phase 4
30A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaRecruitingNCT01868828Phase 4
31Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaRecruitingNCT01249690Phase 4
32Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaRecruitingNCT02773550Phase 4
33Modified Bortezomib-based Combination Therapy for Multiple MyelomaRecruitingNCT02559154Phase 4
34Prolonged Protection From Bone Disease in Multiple MyelomaRecruitingNCT02286830Phase 4
35PDD vs PAD to Treat Initially Diagnosed MMRecruitingNCT02577783Phase 4
36Stage I Multiple Myeloma TreatmentActive, not recruitingNCT00733538Phase 4
37Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseActive, not recruitingNCT01087008Phase 4
38Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple MyelomaActive, not recruitingNCT00777881Phase 4
39Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple MyelomaActive, not recruitingNCT01731886Phase 4
40Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving PlerixaforActive, not recruitingNCT01362972Phase 4
41Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple MyelomaAvailableNCT02477891Phase 4
42Pseudohyponatremia of Multiple Myeloma is True HyponatremiaNot yet recruitingNCT01425606Phase 4
43Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.Not yet recruitingNCT02006225Phase 4
44Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01100879Phase 4
45A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin BTerminatedNCT02608060Phase 4
46Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple MyelomaWithdrawnNCT01410929Phase 4
47Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.WithdrawnNCT00242528Phase 4
48Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving ChemotherapyCompletedNCT00002850Phase 3
49Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaCompletedNCT01324947Phase 3
50Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedNCT00090493Phase 2, Phase 3

Search NIH Clinical Center for Multiple Myeloma

Inferred drug relations via UMLS65/NDF-RT43:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Myeloma cell therapies at LifeMap Discovery.

Genetic Tests for Multiple Myeloma

About this section

Genetic tests related to Multiple Myeloma:

id Genetic test Affiliating Genes
1 Multiple Myeloma22 LIG4

Anatomical Context for Multiple Myeloma

About this section

MalaCards organs/tissues related to Multiple Myeloma:

33
Bone, Bone marrow, T cells, B cells, Breast, Kidney, Testes

FMA organs/tissues related to Multiple Myeloma:

16
The plasma cells in bone marrow

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Myeloma:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Affected by disease

Animal Models for Multiple Myeloma or affiliated genes

About this section

MGI Mouse Phenotypes related to Multiple Myeloma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000200610.3CCND1, CCND3, CD19, FGFR3, IL6, IL6R
2MP:000363110.0CCND1, CD19, DKK1, FGFR3, IL6, IL6R
3MP:000538610.0CCND1, CCND3, CD19, CRBN, FGFR3, IL6
4MP:00053879.9CCND1, CCND3, CD19, FGFR3, IL6, IL6R
5MP:00107689.6CCND1, CCND3, CD19, DKK1, FGFR3, IL6
6MP:00053789.5CCND1, CCND3, CD19, CRBN, DKK1, FGFR3

Publications for Multiple Myeloma

About this section

Articles related to Multiple Myeloma:

(show top 50)    (show all 3239)
idTitleAuthorsYear
1
A case of multiple myeloma presenting as a distal renal tubular acidosis with extensive bilateral nephrolithiasis. (26998308)
2016
2
Effect of Melphalan 140 mg/m(2) versus 200 mg/m(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation - A single center experience. (27219740)
2016
3
Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. (26185631)
2015
4
KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. (26109433)
2015
5
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. (25898974)
2015
6
Cryptosporidiosis causing severe persistent diarrhea in a patient with multiple myeloma: A Case report and brief review of literature. (25006294)
2014
7
LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. (25460501)
2014
8
Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma. (24995304)
2014
9
Treatment of multiple myeloma bone disease: experimental and clinical data. (25388648)
2014
10
N-cadherin impedes proliferation of the multiple myeloma cancer stem cells. (24396705)
2013
11
An old drug with a new future: bendamustine in multiple myeloma. (24053161)
2013
12
Cytogenetic classification in Korean multiple myeloma patients: Prognostic significance of hyperdiploidy with 47 to 50 chromosomes and the number of structural abnormalities. (24372944)
2013
13
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. (24337419)
2013
14
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. (23446999)
2013
15
Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma-to strengthen the case toward renal replacement therapy? (25356216)
2013
16
The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines. (22792345)
2012
17
Effects of short-hairpin RNA-inhibited I^-catenin expression on the growth of human multiple myeloma cells in vitro and in vivo. (22609776)
2012
18
Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. (21420464)
2011
19
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. (21063407)
2010
20
Thrombotic thrombocytopenic purpura associated with disseminated varicella zoster in a multiple myeloma patient. (21260958)
2010
21
Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? (19762082)
2010
22
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. (20920357)
2010
23
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. (20011976)
2009
24
MDR1 diplotypes as prognostic markers in multiple myeloma. (18408561)
2008
25
Tc-99m sestamibi uptake mimicking parathyroid adenoma in a patient with primary hyperparathyroidism and occult multiple myeloma. (18287846)
2008
26
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. (17640854)
2007
27
Chemokines in multiple myeloma. (16982321)
2006
28
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. (17043023)
2006
29
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. (16870555)
2006
30
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. (15902294)
2005
31
Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. (15531906)
2005
32
The structure, expression and function prediction of DAZAP2, a down-regulated gene in multiple myeloma. (15629043)
2004
33
Advances in biology and therapy of multiple myeloma. (14633785)
2003
34
Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. (10914939)
2000
35
CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. (9823960)
1998
36
Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma. (9458238)
1998
37
Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. (9558394)
1998
38
Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma. (9373192)
1997
39
Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. (9815779)
1997
40
Amyotrophic lateral sclerosis associated with multiple myeloma, endocrinopathy and skin changes suggestive of a POEMS syndrome variant. (7595623)
1995
41
Interferon-gamma in multiple myeloma. (8535185)
1995
42
Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. (7522395)
1994
43
Objective response of multiple myeloma to cyclosporin A. (7696923)
1994
44
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. (1391937)
1992
45
Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. (2031968)
1991
46
Panhypopituitarism due to multiple myeloma. (5415797)
1970
47
48
49
50

Variations for Multiple Myeloma

About this section

Clinvar genetic disease variations for Multiple Myeloma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1FGFR3NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu)single nucleotide variantPathogenicrs78311289GRCh37Chr 4, 1807889: 1807889
2FGFR3NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys)single nucleotide variantPathogenicrs121913482GRCh37Chr 4, 1803564: 1803564
3FGFR3FGFR3, FGFR3/IGH FUSIONundetermined variantPathogenic

Expression for genes affiliated with Multiple Myeloma

About this section
Search GEO for disease gene expression data for Multiple Myeloma.

Pathways for genes affiliated with Multiple Myeloma

About this section

GO Terms for genes affiliated with Multiple Myeloma

About this section

Biological processes related to Multiple Myeloma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1hepatic immune responseGO:000238410.9IL6, IL6R
2T-helper 17 cell lineage commitmentGO:007254010.8IL6, IRF4
3type I interferon signaling pathwayGO:006033710.8BST2, IRF4
4response to X-rayGO:001016510.8CCND1, LIG4
5defense response to protozoanGO:004283210.7IL6, IRF4
6positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.7IL6, IL6R
7negative regulation of collagen biosynthetic processGO:003296610.7IL6, IL6R
8positive regulation of leukocyte chemotaxisGO:000269010.4IL6, IL6R
9cytokine-mediated signaling pathwayGO:001922110.1BST2, IL6, IL6R, IRF4

Molecular functions related to Multiple Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.4CD19, FGFR3

Sources for Multiple Myeloma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet